Form 10-K IDEAYA Biosciences, Inc For: Dec 31 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Jan 09 2021 Read 345 Times
Revitope Oncology Inc and leading Chinese biopharmaceutical company Junshi Biosciences, are collaborating on the development of precision cancer therapies that harness the body’s immune response to kill cancer cells while leaving healthy body tissues untouched.
The Birmingham spin-out will leverage its proprietary protein engineering platform with Junshi’s novel antibody components to develop first-in-class dual antigen targeting cancer therapies. Revitope will receive up to $160 million per molecule in milestones and royalties on net sales of 10%. Junshi has also committed to acquire a 9.99% stake in Revitope for $10 million.
Revitope’s technology known as the T-cell engager antibody circuit (TEAC), splits antibodies into two halves which are programmed to recognise different antigens. The two halves are inactive until they encounter a cancer cell that is expressing both antigens, when they reunite and direct the body’s immune response to kill